Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548327 · ClinicalTrials.gov registry record · Phase 2
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
A Phase 2 study, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00548327 is a Phase 2 study that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 11 participants.
The verdict
NCT00548327, a Phase 2 study, was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain.
Interventions
- DRUG Placebo
- DRUG Atomoxetine
- PROCEDURE Neuropsychological Testing
- PROCEDURE Functional magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548327
The ClinicalTrials.gov registry entry for NCT00548327 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00548327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548327 about?
NCT00548327 is a clinical study titled "The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype". This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopam...
What is the current status of trial NCT00548327?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2007-10. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00548327?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG), Neuropsychological Testing (PROCEDURE), Functional magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00548327?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.